Develops Antibody Drug Conjugates (ADCs) for cancer treatment. Focuses on therapies for hematological malignancies (blood cancers) and solid tumors. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 24% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 1.7× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 6% of them.
Analysts' average target sits 227% above today's price.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
An investor who bought at the very peak is down 97% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 4 years, sales grew about 24% a year on average.
Sales run at $81.4M a year. A small number, but proof the product has real buyers.
A loss of $142.6M against $81.4M in annual sales.
At the current pace of spending, the cash lasts about 1.8 years. After that, the company needs to find new money.
On our five-subject report card, ADCT sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: ADCT is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (6/100) says the stock isn’t cheap.